Back to search

Peptide record

TPDB43311

Anticancer modified_plain modified
5 amino acids
Basic Information
TPDB43311
Anticancer
Cancer-related peptides
CancerPPD 2.0 Peptipedia SATPdb dbACP
modified_plain
Yes
A 5-aa modified anticancer peptide sequence curated from CancerPPD 2.0, Peptipedia, SATPdb, and other sources, without an available 3D structural model.
Chemical: A* = Cα -dialkylated glycine (Aaa2,2 )
Sequence
YRA*G
Physicochemical Analysis
C20H31N7O6
NDCEQHILKMFPSTWV
ARGY
465.51
9.88
1
0
2
+1
-0.29
-0.880
20.00
Mammalian: 2.8 hour Yeast: 10 min E.coli: 2 min
1490
320.08
1
Residue Composition
number
1
A
1
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
0
L
0
K
0
M
0
F
0
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 1 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 0 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
5
C20H31N7O6
465.51
9.88
+1
-0.29
-0.880
Free
A* = Cα -dialkylated glycine (Aaa2,2 )
L
Linear
Free
Antitumor
Synthetic Peptide
Evidence Records 24 records
Evidence 1 Activity

Activity

4.6% inhibition at 10-6M
Anticancer

Target

Larynx Cancer
HEp-2
Larynx

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

4.9% inhibition at 10-5M
Anticancer

Target

Larynx Cancer
HEp-2
Larynx

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 3 Activity

Activity

12.6% inhibition at 10-4M
Anticancer

Target

Larynx Cancer
HEp-2
Larynx

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 4 Activity

Activity

26.4% inhibition at 10-3M
Anticancer

Target

Larynx Cancer
HEp-2
Larynx

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 5 Activity

Activity

11.0% inhibition at 10-6M
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 6 Activity

Activity

11.7% inhibition at 10-5M
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 7 Activity

Activity

11.6% inhibition at 10-4M
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 8 Activity

Activity

28.2% inhibition at 10-3M
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 9 Activity

Activity

1.2% inhibition at 10-5M
Anticancer

Target

Skin Cancer
HBL
Skin

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 10 Activity

Activity

3.3% inhibition at 10-4M
Anticancer

Target

Skin Cancer
HBL
Skin

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 11 Activity

Activity

19.4% inhibition at 10-3M
Anticancer

Target

Skin Cancer
HBL
Skin

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 12 Activity

Activity

7.6% inhibition at 10-6M
Anticancer

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 13 Activity

Activity

3.8% inhibition at 10-5M
Anticancer

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 14 Activity

Activity

12.4% inhibition at 10-4M
Anticancer

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 15 Activity

Activity

22.4% inhibition at 10-3M
Anticancer

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 16 Activity

Activity

17.0% inhibition at 10-6M
Anticancer

Target

Colon Cancer
SW-620
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 17 Activity

Activity

13.5% inhibition at 10-5M
Anticancer

Target

Colon Cancer
SW-620
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 18 Activity

Activity

13.5% inhibition at 10-4M
Anticancer

Target

Colon Cancer
SW-620
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 19 Activity

Activity

25.3% inhibition at 10-3M
Anticancer

Target

Colon Cancer
SW-620
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 20 Activity

Activity

8.1% inhibition at 10-6M
Anticancer

Target

Colon Cancer
CaCo-2
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 21 Activity

Activity

6.9% inhibition at 10-5M
Anticancer

Target

Colon Cancer
CaCo-2
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 22 Activity

Activity

8.1% inhibition at 10-4M
Anticancer

Target

Colon Cancer
CaCo-2
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 23 Activity

Activity

8.6% inhibition at 10-3M
Anticancer

Target

Colon Cancer
CaCo-2
Colon

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 24 Activity

Activity

15.6% inhibition at 10-3M
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
10.79-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006